EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 292 (2021) E3S Web Conf., 292 (2021) 03092 References
Open Access
Issue
E3S Web Conf.
Volume 292, 2021
2021 2nd International Conference on New Energy Technology and Industrial Development (NETID 2021)
Article Number 03092
Number of page(s) 10
Section Environmental Sustainable Development and Industrial Transformation
DOI https://doi.org/10.1051/e3sconf/202129203092
Published online 09 September 2021
  1. Oberfeld, B., Achanta, A., Carpenter, K., Chen, P., Gilette, N. M., Langat, P., Said, J. T., Schiff, A. E., Zhou, A. S., Barczak, A. K & Pillai, S. SnapShot: COVID-19. Cell, 181,954-954,(2020). [CrossRef] [PubMed] [Google Scholar]
  2. Huang, Y., Yang, C., Xu, X. F., Xu, W, & Liu, S. W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacal Sin. 41, (2020). [Google Scholar]
  3. Schoeman, D. & Fielding, B. C. Coronavirus envelope protein: current knowledge. Virol J 16, (2019). [CrossRef] [PubMed] [Google Scholar]
  4. Chen, C. Y. et al. Structure of the SARS coronavirus nucleocapsid protein RNA-binding dimerization domain suggests a mechanism for helical packaging of viral RNA. J Mol Biol 368, 1075-1086, (2007). [CrossRef] [PubMed] [Google Scholar]
  5. Nie et al., Multi-organ proteomic landscape of COVID-19 autopsies. Cell, 184, 775-791 e14.(2021). [CrossRef] [PubMed] [Google Scholar]
  6. Puntmann et al., Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol, 5, (2020). [Google Scholar]
  7. Feldstein et al., Characteristics and Outcomes of US children and Adolescents with multisystem inflammatory syndrome in Children(MIS-C) Compared with severe acute COVID-19. JAMA, 325, (2021). [Google Scholar]
  8. Frontera et al., Toxic Metabolic Encephalopathy in Hospitalized Patients with COVID-19. Neurocrit Cara. (2021) [Google Scholar]
  9. Corman, V. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 25, (2020). [Google Scholar]
  10. Gorzalski, A. J. et al. High-Throughput Transcription-mediated amplification on the Hologic Panther is a highly sensitive method of detection for SARS-CoV-2. J. Clin. Virol. 129, 104501 (2020). [CrossRef] [PubMed] [Google Scholar]
  11. Zhang, W. et al. CRISPR-Based Approaches for Efficient and Accurate Detection of SARS-CoV-2. Lab. Med. (2020). [Google Scholar]
  12. Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7). http://en.nhc.gov.cn/2020-03/29/c_78469.htm. [Google Scholar]
  13. Rapid, Ultrasensitive, and Quantitative Detection of SARS-CoV-2 Using Antisense Oligonucleotides Directed Electrochemical Biosensor Chip | ACS Nano. https://pubs.acs.org/doi/10.1021/acsnano.0c06392#. [Google Scholar]
  14. Adams, E. R. et al. Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. Wellcome Open Res. 5, (2020). [Google Scholar]
  15. Shen, B. et al. Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG. Am. J. Transl. Res. 12, 1348–1354 (2020). [Google Scholar]
  16. W, Z. et al. CRISPR-Based Approaches for Efficient and Accurate Detection of SARS-CoV-2. Lab. Med. 52, 116–121 (2021). [CrossRef] [PubMed] [Google Scholar]
  17. KALETR A® (lopinavir/ritonavir) capsules, <https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021226s035lbl.pdf> (2011). [Google Scholar]
  18. Simonis, A., Theobald, S., Fätkenheuer, G., Rybniker, J. & Malin, J. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Molecular Medicine 13, (2021). [CrossRef] [Google Scholar]
  19. Uzunova, K., Filipova, E., Pavlova, V. & Vekov, T. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomedicine & Pharmacotherapy 131, 110668 (2020). [CrossRef] [Google Scholar]
  20. Samudrala, P. et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. European Journal of Pharmacology 883, 173375 (2020). [CrossRef] [PubMed] [Google Scholar]
  21. Singh, T. et al. Drug repurposing approach to fight COVID-19. Pharmacological Reports 72, 1479-1508 (2020). [CrossRef] [Google Scholar]
  22. Sun, J. et al. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgrad Med 132, 604-613 (2020). [CrossRef] [PubMed] [Google Scholar]
  23. Eastman, R. et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science 6, 672-683 (2020). [CrossRef] [PubMed] [Google Scholar]
  24. Singh, A., Singh, A., Singh, R. & Misra, A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14, 641-648 (2020). [CrossRef] [Google Scholar]
  25. Frediansyah, A., Nainu, F., Dhama, K., Mudatsir, M. & Harapan, H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clinical Epidemiology and Global Health 9, 123-127 (2021). [CrossRef] [PubMed] [Google Scholar]
  26. Lam, S., Lombardi, A. & Ouanounou, A. COVID-19: A review of the proposed pharmacological treatments. European Journal of Pharmacology 886, 173451 (2020). [CrossRef] [PubMed] [Google Scholar]
  27. Nojomi, M. et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infectious Diseases 20, (2020). [CrossRef] [PubMed] [Google Scholar]
  28. Steckelberg, A., Florit, G., Alcantara, C. & Johnson, C. (2021). at <https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update-coronavirus/> [Google Scholar]
  29. The different types of COVID-19 vaccines. Who.int at https://www.who.int/news-room/feature-stories/detail/the-race-for-a-covid-19-vaccine-explained [Google Scholar]
  30. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. (2021). [PubMed] [Google Scholar]
  31. Vaccine Type. Live-attenuated vaccines. (2020).at https://www.hhs.gov/immunization/basics/types/index.html (2021). [Google Scholar]
  32. Gil, C. et al. A DIVA vaccine strain lacking RpoS and the secondary messenger c-di-GMP for protection against salmonellosis in pigs. (2021). [Google Scholar]
  33. Tretyakova, I., Lukashevich, I., Glass, P., Wang, E., Weaver, S. and Pushko, P. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. (2021). [Google Scholar]
  34. Zou, J., Xie, X., Luo, H., Shan, C., Muruato, A., Weaver, S., Wang, T. and Shi, P. A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity. (2021). [Google Scholar]
  35. Plotkin, S. A., Orenstein, W. A., & Offit, P. A. Plotkin’s vaccines at http://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20130189143. (2018). [Google Scholar]
  36. Information about the J&J/Janssen COVID-19 Vaccine. Centers for Disease Control and Prevention (2021). at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html (2021). [Google Scholar]
  37. Cdc.gov.[online] at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-Villafana.pdf (2021). [Google Scholar]
  38. Zimmer, C., Corum, J. and Wee, S., Coronavirus Vaccine Tracker. [online] Nytimes.com. at: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html (2021). [Google Scholar]
  39. Gavi.org. What are whole virus vaccines and how could they be used against COVID-19? at https://www.gavi.org/vaccineswork/what-are-whole-virus-vaccines-and-how-could-they-be-used-against-covid-19 (2021). [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.